First dosing of Pfizer DART candidate in phase 1 trial triggers $2m milestone payment to MacroGenics
MacroGenics announced that its collaboration partner, Pfizer, has advanced a bispecific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting, or DART, platform.
Click on this link for more information.
